We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.27, which surpassed the Zacks Consensus Estimate by 8.10%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.74%.
IDEXX’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.19 billion, indicating an increase of 7.5% from the year-ago figure.
The Zacks Consensus Estimate for EPS is pinned at $3.71, implying a rise of 9.1% from the year-ago figure.
Estimate Revision Trend Ahead of IDEXX’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to the announcement.
Key Drivers of IDEXX’s Q3 Performance
Companion Animal Group (“CAG”)
The business is likely to have sustained its momentum in the third quarter of 2026, supported by continued volume growth. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions.
IDEXX VetLab consumables might have benefited from volume expansion driven by net new customer gains in the premium instrument installed base and expanded testing utilization. Global Reference Lab revenues are likely to have benefited from an expanding customer base and increased same-store utilization, as existing customers adopted a broader testing menu, such as IDEXX Cancer Dx. Global Rapid Assay revenues are expected to have improved as the impact of customers transitioning pancreatic lipase testing to the Catalyst instrument platform gradually subsides.
Within Veterinary Software, Services and Diagnostic Imaging Systems, recurring revenue growth was likely supported by expanding cloud-based PIMS recurring revenues and increased adoption of the newly launched DR50 Plus platform. Additionally, the September acquisition of CoVetAI Inc. is expected to strengthen IDEXX’s global software presence through integration with IDEXX VetConnect PLUS while addressing the needs of veterinary practice teams in markets not currently served by its practice management systems.
On the flip side, continued pressure on wellness visits might have remained a key constraint on clinical visit growth during the third quarter.
The Zacks Consensus Estimate for CAG’s third-quarter business revenues implies an increase of 7.9%.
Water
The segment’s revenues are expected to have benefited from both the United States and international regions, including benefits from order recovery in the Middle East.
The Zacks Consensus Estimate for Water’s revenues implies 6.4% year-over-year growth.
Revenues in this division might have gained from an increase in test volumes across all regions.
The Zacks Consensus Estimate for LPD revenues indicates a 3.5% year-over-year increase.
What Our Model Says About IDXX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: IDEXX Laboratories has an Earnings ESP of +0.59%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other medical stocks worth considering, as these too have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
Key Takeaways
IDEXX Laboratories, Inc. (IDXX - Free Report) is set to release third-quarter 2026 results on Nov. 2, before the opening bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.27, which surpassed the Zacks Consensus Estimate by 8.10%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.74%.
IDEXX’s Q3 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.19 billion, indicating an increase of 7.5% from the year-ago figure.
The Zacks Consensus Estimate for EPS is pinned at $3.71, implying a rise of 9.1% from the year-ago figure.
Estimate Revision Trend Ahead of IDEXX’s Q3 Earnings
Estimates for third-quarter earnings have remained unchanged in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to the announcement.
Key Drivers of IDEXX’s Q3 Performance
Companion Animal Group (“CAG”)
The business is likely to have sustained its momentum in the third quarter of 2026, supported by continued volume growth. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions.
IDEXX VetLab consumables might have benefited from volume expansion driven by net new customer gains in the premium instrument installed base and expanded testing utilization. Global Reference Lab revenues are likely to have benefited from an expanding customer base and increased same-store utilization, as existing customers adopted a broader testing menu, such as IDEXX Cancer Dx. Global Rapid Assay revenues are expected to have improved as the impact of customers transitioning pancreatic lipase testing to the Catalyst instrument platform gradually subsides.
Within Veterinary Software, Services and Diagnostic Imaging Systems, recurring revenue growth was likely supported by expanding cloud-based PIMS recurring revenues and increased adoption of the newly launched DR50 Plus platform. Additionally, the September acquisition of CoVetAI Inc. is expected to strengthen IDEXX’s global software presence through integration with IDEXX VetConnect PLUS while addressing the needs of veterinary practice teams in markets not currently served by its practice management systems.
On the flip side, continued pressure on wellness visits might have remained a key constraint on clinical visit growth during the third quarter.
The Zacks Consensus Estimate for CAG’s third-quarter business revenues implies an increase of 7.9%.
Water
The segment’s revenues are expected to have benefited from both the United States and international regions, including benefits from order recovery in the Middle East.
The Zacks Consensus Estimate for Water’s revenues implies 6.4% year-over-year growth.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote
Livestock, Poultry and Dairy (“LPD”)
Revenues in this division might have gained from an increase in test volumes across all regions.
The Zacks Consensus Estimate for LPD revenues indicates a 3.5% year-over-year increase.
What Our Model Says About IDXX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is exactly the case here, as you can see below:
Earnings ESP: IDEXX Laboratories has an Earnings ESP of +0.59%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Top MedTech Picks
Here are some other medical stocks worth considering, as these too have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.